# Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/triple-hormone-receptor-agonist-retatrutide-for-obesity-a-phase-2-trial/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Ania M. Jastreboff,Lee M. Kaplan,Juan P. Frías,Qiwei Wu,Yu Du,Sirel Gurbuz,Tamer Coskun,Axel Haupt,Zvonko Miličević,Mark L. Hartman |
| Citations | 1,028 |
| DOI | 10.1056/nejmoa2301972 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4382049661 |
| PMID | 37366315 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Axel Haupt](https://scholariq.org/researchers/axel-haupt/)

## Paper journal

- [New England Journal of Medicine](https://scholariq.org/journals/new-england-journal-of-medicine/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)
- [Pharmacology and Obesity Treatment](https://scholariq.org/topics/pharmacology-and-obesity-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.